a recombinant ace2 standard curve  (R&D Systems)

Journal:

Article Title: Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure

doi: 10.1016/j.jacc.2008.02.088

Figure Lengend Snippet: (A) rACE2 (25 ng/ml) was mixed with 30% commercial human plasma in the presence of different concentrations of the specific ACE2 inhibitor D×600, and ACE2 activity was determined after incubation for 18 h. Data are expressed as the percentage of ACE2 activity of rACE2. (B) Thirty percent human plasma (patient sample) was pre-incubated with either D×600 (1 µmol/l), anti-human ACE2 polyclonal antibody, or isotype-matched control antibodies for 30 min and then ACE2 activity was determined at 4 and 18 h. One of 3 representative experiments is shown. ACE = angiotensin-converting enzyme; IgG = immunoglobulin G; rACE2 = recombinant angiotensin-converting enzyme 2 activity; SACE = soluble angiotensin-converting enzyme.

Article Snippet: Values were normalized to a recombinant ACE2 standard curve (R&D Systems).

Techniques: Activity Assay, Incubation, Recombinant

Journal:

Article Title: Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure

doi: 10.1016/j.jacc.2008.02.088

Figure Lengend Snippet: Quartile plots are shown. One-way analysis of variance, p = 0.0067. Number of patients (n) is given for each group. HF = heart failure; NYHA = New York Heart Association; sACE2 = soluble angiotensin-converting enzyme 2 activity.

Article Snippet: Values were normalized to a recombinant ACE2 standard curve (R&D Systems).

Techniques: Activity Assay